MedTrace Logo

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

NCT03559270 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2022-11-08

Study results available
· View outcomes & findings →

Summary

This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).

Conditions

Interventions

DRUG

Baricitinib

Administered orally

Sponsors & Collaborators

Principal Investigators

  • 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-27
Primary Completion
2021-10-14
Completion
2022-06-13
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03559270 on ClinicalTrials.gov